Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Chao, Wu, Jiao, Chen, Yin, Nie, Jianyun, Chen, Ceshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005514/
https://www.ncbi.nlm.nih.gov/pubmed/33790792
http://dx.doi.org/10.3389/fphar.2021.628690
_version_ 1783672123003240448
author Dong, Chao
Wu, Jiao
Chen, Yin
Nie, Jianyun
Chen, Ceshi
author_facet Dong, Chao
Wu, Jiao
Chen, Yin
Nie, Jianyun
Chen, Ceshi
author_sort Dong, Chao
collection PubMed
description Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer.
format Online
Article
Text
id pubmed-8005514
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80055142021-03-30 Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer Dong, Chao Wu, Jiao Chen, Yin Nie, Jianyun Chen, Ceshi Front Pharmacol Pharmacology Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease recurrence in most breast cancer patients, many patients exhibit acquired resistance. Hyperactivation of the PI3K/AKT/mTOR pathway is associated with drug resistance and cancer progression. Currently, a number of drugs targeting PI3K/AKT/mTOR are being investigated in clinical trials by combining them with standard therapies to overcome acquired resistance in breast cancer. In this review, we summarize the critical role of the PI3K/AKT/mTOR pathway in drug resistance, the development of PI3K/AKT/mTOR inhibitors, and strategies to overcome acquired resistance to standard therapies in breast cancer. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005514/ /pubmed/33790792 http://dx.doi.org/10.3389/fphar.2021.628690 Text en Copyright © 2021 Dong, Wu, Chen, Nie and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dong, Chao
Wu, Jiao
Chen, Yin
Nie, Jianyun
Chen, Ceshi
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title_full Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title_fullStr Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title_full_unstemmed Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title_short Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
title_sort activation of pi3k/akt/mtor pathway causes drug resistance in breast cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005514/
https://www.ncbi.nlm.nih.gov/pubmed/33790792
http://dx.doi.org/10.3389/fphar.2021.628690
work_keys_str_mv AT dongchao activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer
AT wujiao activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer
AT chenyin activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer
AT niejianyun activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer
AT chenceshi activationofpi3kaktmtorpathwaycausesdrugresistanceinbreastcancer

Ejemplares similares